BRPI0820779B8 - compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos - Google Patents

compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos

Info

Publication number
BRPI0820779B8
BRPI0820779B8 BRPI0820779A BRPI0820779A BRPI0820779B8 BR PI0820779 B8 BRPI0820779 B8 BR PI0820779B8 BR PI0820779 A BRPI0820779 A BR PI0820779A BR PI0820779 A BRPI0820779 A BR PI0820779A BR PI0820779 B8 BRPI0820779 B8 BR PI0820779B8
Authority
BR
Brazil
Prior art keywords
compounds
amino
preparing
pharmaceutical composition
pyrimidine derivative
Prior art date
Application number
BRPI0820779A
Other languages
English (en)
Portuguese (pt)
Inventor
Carceller González Elena
Maria Medina Fuentes Eva
Martí Via Josep
Virgili Bernadó Marina
Soliva Soliva Robert
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of BRPI0820779A2 publication Critical patent/BRPI0820779A2/pt
Publication of BRPI0820779B1 publication Critical patent/BRPI0820779B1/pt
Publication of BRPI0820779B8 publication Critical patent/BRPI0820779B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0820779A 2007-12-21 2008-12-18 compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos BRPI0820779B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07382006 2007-12-21
US3153408P 2008-02-26 2008-02-26
PCT/EP2008/067950 WO2009080721A2 (en) 2007-12-21 2008-12-18 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0820779A2 BRPI0820779A2 (pt) 2015-06-16
BRPI0820779B1 BRPI0820779B1 (pt) 2020-02-04
BRPI0820779B8 true BRPI0820779B8 (pt) 2021-05-25

Family

ID=39473347

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820779A BRPI0820779B8 (pt) 2007-12-21 2008-12-18 compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos

Country Status (24)

Country Link
US (1) US8431580B2 (enExample)
EP (1) EP2235012B1 (enExample)
JP (1) JP5498396B2 (enExample)
KR (1) KR101639819B1 (enExample)
CN (1) CN101903385B (enExample)
AR (1) AR069814A1 (enExample)
AU (1) AU2008341678B2 (enExample)
BR (1) BRPI0820779B8 (enExample)
CA (1) CA2709650C (enExample)
CL (1) CL2008003811A1 (enExample)
CY (1) CY1114427T1 (enExample)
DK (1) DK2235012T3 (enExample)
ES (1) ES2430210T3 (enExample)
HR (1) HRP20130918T1 (enExample)
IL (1) IL206413A (enExample)
PE (1) PE20091330A1 (enExample)
PL (1) PL2235012T3 (enExample)
PT (1) PT2235012E (enExample)
RU (1) RU2489430C2 (enExample)
SI (1) SI2235012T1 (enExample)
TW (1) TWI429440B (enExample)
UA (1) UA101963C2 (enExample)
WO (1) WO2009080721A2 (enExample)
ZA (1) ZA201005179B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EA019320B1 (ru) 2008-12-22 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
JP5759471B2 (ja) 2009-10-29 2015-08-05 ヴェクチュラ リミテッド Ｊａｋ３キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体
JP5781537B2 (ja) * 2009-12-23 2015-09-24 メディシス ファーマシューティカル コーポレイション ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2361869C2 (ru) * 2002-02-05 2009-07-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые арил- и гетероарилпиперазины
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
CA2551944A1 (en) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
DE602006020864D1 (de) * 2005-04-11 2011-05-05 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
US20090306038A1 (en) * 2005-09-13 2009-12-10 Carceller Gonzalez Elena 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
WO2007084914A2 (en) * 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists

Also Published As

Publication number Publication date
CN101903385B (zh) 2013-11-06
PE20091330A1 (es) 2009-09-07
IL206413A (en) 2015-06-30
WO2009080721A2 (en) 2009-07-02
JP2011506566A (ja) 2011-03-03
PT2235012E (pt) 2013-08-28
CL2008003811A1 (es) 2009-05-22
US8431580B2 (en) 2013-04-30
KR101639819B1 (ko) 2016-07-14
EP2235012B1 (en) 2013-07-17
ZA201005179B (en) 2012-03-28
BRPI0820779A2 (pt) 2015-06-16
AU2008341678A1 (en) 2009-07-02
CA2709650A1 (en) 2009-07-02
WO2009080721A3 (en) 2009-09-11
TW200938197A (en) 2009-09-16
JP5498396B2 (ja) 2014-05-21
UA101963C2 (en) 2013-05-27
TWI429440B (zh) 2014-03-11
SI2235012T1 (sl) 2013-11-29
PL2235012T3 (pl) 2013-12-31
KR20100096184A (ko) 2010-09-01
AU2008341678B2 (en) 2013-03-21
EP2235012A2 (en) 2010-10-06
CA2709650C (en) 2016-06-07
RU2010130418A (ru) 2012-01-27
CY1114427T1 (el) 2016-08-31
ES2430210T3 (es) 2013-11-19
DK2235012T3 (da) 2013-10-07
HRP20130918T1 (hr) 2013-11-08
BRPI0820779B1 (pt) 2020-02-04
US20110039817A1 (en) 2011-02-17
RU2489430C2 (ru) 2013-08-10
HK1149003A1 (en) 2011-09-23
CN101903385A (zh) 2010-12-01
IL206413A0 (en) 2010-12-30
AR069814A1 (es) 2010-02-17

Similar Documents

Publication Publication Date Title
BRPI0514681A (pt) derivados de pirimidina
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
CR20110309A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
DOP2011000176A (es) Compuestos organicos
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0519674A2 (pt) sulfonil pirrolidinas, mÉtodo para produzir as mesmas e seu uso como drogas
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
ATE483707T1 (de) 2-cyclopropylthiazolderivate
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
ECSP077259A (es) Derivados de pirimidina
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
ECSP088326A (es) Derivados de benzotiazol ciclobutil amina y su uso como ligandos de los receptores 3 de histamina
BRPI0815360A8 (pt) Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008855B8 (pt) derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
BRPI0820838B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: PALAU PHARMA, S.A.U. (ES)

B25D Requested change of name of applicant approved

Owner name: PALAU PHARMA, S.L.U. (ES)